Nitinotes is a privately-held medical device company based in Caesarea Israel. Its flagship product is the endozip™, a novel gastroscopic solution for safer, simpler GI suturing. Backed by preclinical success and prominent KOLs, Nitinotes’s gastric volume restriction provides an effective, minimally-invasive solution to class 1 and 2 obesity patients, for the majority of whom gold-standard bariatric surgery is uncovered and/or inadvisable.
In a series of animal studies and ex-vivo tests on fresh human tissue remains from sleeve gastrectomy, endozip™ has shown promising results, with a reproducible technique. Recently, Nitinotes has successfully performed a FIH study in Spain, led by Dr. Lopez Nava, director of bariatric endoscopy at HM Sanchinarro University Hospital, Madrid.
Nitinotes is headed by a team of R&D
and business experts, including: